BUSINESSCNBC TOP
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Zealand Pharma's stock experienced its two worst days on record as market enthusiasm for one of its experimental drugs waned. Investors are now focusing on amylin-based medicines as a potential growth driver for the company.
Related Signal
Adjacent reporting
- Weight loss drug maker sinks 25% after new safety data spooks investors
- Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance
- Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug
- Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
- Cheaper protein shakes are crushing this industry stalwart